GUTS - Fractyl Health, Inc Total Debt to Capital

Fractyl Health, Inc. (GUTS) is developing innovative gene therapies to combat diabetes and obesity, leveraging the potential of the Rejuvenate system and interest from corporate behemoths. Simultaneously, the business is implementing ESG principles by optimizing energy costs and research ethics. The verified price history on the GURU.Markets platform chart reflects a debt-to-equity ratio of 0.00, complemented by the full capacity utilization of its own modernized plants.

Developing an innovative mucosal regeneration method for diabetes treatment requires significant capital investment in a technological moat for Fractyl Health, Inc. (GUTS). Analyzing the debt-to-equity chart, an investor assesses the proportion of total liabilities to net assets, which determines the degree of financial leverage and the stability of the business's funding structure in the face of market volatility.